In a postpartum patient with suspected pulmonary embolism, should therapeutic enoxaparin (low‑molecular‑weight heparin) be started now?

Yes, start therapeutic enoxaparin immediately in a postpartum patient with suspected pulmonary embolism.

In postpartum patients with suspected PE, therapeutic anticoagulation with low-molecular-weight heparin (LMWH) should be initiated immediately while diagnostic workup proceeds—do not delay treatment pending imaging confirmation. 1, 2

Rationale for Immediate Anticoagulation

Pulmonary embolism remains a leading cause of maternal mortality in developed countries 3, 4. The postpartum period carries the highest risk for venous thromboembolism, particularly after cesarean delivery 3. Given the potentially fatal consequences and the safety profile of LMWH in the postpartum period, the risk-benefit calculation strongly favors immediate therapeutic anticoagulation when PE is suspected.

Key Clinical Considerations:

• LMWH is the treatment of choice during pregnancy and postpartum 1, 2
• Treatment should continue until 6 weeks after delivery with a minimum total duration of 3 months 1
• LMWH does not preclude breastfeeding 1
• Enoxaparin is available in multiple therapeutic dosing options (60mg, 80mg, 100mg, 120mg, 150mg subcutaneous) 5

Diagnostic Approach While Treating

While anticoagulation is initiated, pursue definitive diagnosis:

1. Doppler ultrasound of lower extremities first - if positive for DVT, this confirms VTE and avoids radiation 3, 4
2. If ultrasound negative, proceed to CT pulmonary angiography or ventilation-perfusion scan 3, 4
3. Do not delay imaging due to concerns about radiation - diagnostic tests are not contraindicated in postpartum patients 3

Bleeding Risk Management

The 2018 ASH guidelines 6 note that while there is concern about postpartum hemorrhage with therapeutic LMWH, observational data show:

• Overall risks of postpartum hemorrhage (>500 mL) and severe hemorrhage (>1000 mL) were not significantly increased with therapeutic-dose LMWH
• Subgroup analysis suggested increased risk after vaginal delivery (OR 1.9) or emergency cesarean (OR 11.3), but these were from small studies
• The risk of minor antepartum bleeding was higher with LMWH (RR 2.12), but major bleeding was not significantly increased

The mortality risk from untreated PE far outweighs bleeding concerns in the postpartum period. Case reports demonstrate fatal outcomes when PE is missed or treatment delayed 7, 8.

Special Circumstances

For massive PE with hemodynamic instability (hypotension, shock):

• Catheter-directed therapy may be safer than systemic thrombolysis in postpartum women at high bleeding risk 8, 2
• Systemic thrombolysis can be used but carries significant bleeding risks and should be reserved for high-risk PE with shock 2
• Temporary vena cava filter may be considered if anticoagulation is contraindicated 4

Common Pitfalls to Avoid

• Do not wait for imaging before starting anticoagulation - PE can be rapidly fatal 7
• Do not assume symptoms are normal postpartum changes - dyspnea and chest pain warrant immediate evaluation 8
• Do not withhold LMWH due to breastfeeding concerns - it is safe 1
• Do not use direct oral anticoagulants - safety data in postpartum/breastfeeding is insufficient 6